Insurance access and demand response: Pricing and welfare implications

David Besanko, David Dranove and Craig Garthwaite

Journal of Health Economics, 2020, vol. 73, issue C

Abstract: We present a model in which health insurance allows liquidity-constrained patients access to otherwise unaffordable treatments. A monopolist’s profit-maximizing price for an insured treatment is greater (for any cost sharing) than it would be if the treatment was not covered. Consumer surplus may also be less. These results are based on a different mechanism than would operate in a standard moral hazard model. Our model also provides an economic rationale for the common claim that pharmaceutical firms set prices that exceed the value their products create. We show this problem is exacerbated when health insurance covers additional monopoly-provided services.

Keywords: Pharmaceutical prices; Health insurance access; Liquidity constraints; Complementary monopoly (search for similar items in EconPapers)
JEL-codes: I11 I13 L13 (search for similar items in EconPapers)
Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0167629619305831
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:jhecon:v:73:y:2020:i:c:s0167629619305831

DOI: 10.1016/j.jhealeco.2020.102329

Access Statistics for this article

Journal of Health Economics is currently edited by J. P. Newhouse, A. J. Culyer, R. Frank, K. Claxton and T. McGuire

More articles in Journal of Health Economics from Elsevier
Bibliographic data for series maintained by Catherine Liu ().